Roivant announces positive Phase 2 PHocus mosliciguat results
Roivant says it has positive results from its Phase 2 PHocus trial evaluating mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also unveils an ongoing Phase 3 PHrontier study.
BASEL, Switzerland and LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Roivant NASDAQ:ROIV today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progres…